Inactive

DESCRIPTION The U.S. Department of Health and Human Services (HHS), National Institutes of Health (NIH), National Cancer Institute (NCI), Center for Cancer Research (CCR), Laboratory of Cancer Biology... DESCRIPTION The U.S. Department of Health and Human Services (HHS), National Institutes of Health (NIH), National Cancer Institute (NCI), Center for Cancer Research (CCR), Laboratory of Cancer Biology and Genetics (LCBG) intends to procure, on a sole source basis, monoclonal rabbit antibodies from GenScript USA Inc. 860 Centennial Ave. Piscataway, NJ 08854 The response close date of the notice for this requirement is in accordance with FAR 5.203(b). This acquisition will be processed under FAR Part 12 – Acquisition for Commercial Items and will be made pursuant to the authority in FAR Part 13.106-1(b)(2); and is exempt from the requirements of FAR Part 6. The North American Industry Classification System (NAICS) code is 325413 and the business size standard is 1,250 employees. BACKGROUND Organismal growth relies on conserved nutrient signaling pathways, such as mechanistic Target of Rapamycin (mTOR), that converge amino acids and growth factors to regulate cellular metabolism. Dysregulation of mTOR signaling can result in disease, such cancer, type II diabetes, and neurological disorders. mTOR signaling is divided into unique macromolecular protein complexes, Raptor (mTORC1), Rictor (mTORC2), and most recently, mEAK-7 (mTORC3). Despite the fact that mTOR signaling has been identified as a major driver of a diverse array of cancers worldwide, few therapeutics have shown true efficacy in the suppression of long-term disease. Since the discovery of a third mTOR complex, there has been an increasing probability of the existence of novel mTOR complexes. This would suggest that identifying novel mTOR complexes and understanding the role of mTORC3 signaling in cancer would result in future targets for drug development. This antibody site is predicted to be important for the function of mTORC3 signaling. NCI has already completed preliminary peptide synthesis and inoculation of 5 rabbits for testing. This preliminary testing is essential before moving on to selecting ten individual unique B cells, each of which produces individual unique antibodies in purified form, 0.1mg each with sequencing. TYPE OF ORDER This is a non-severable Firm-Fixed-Price Purchase Order. Funds are only available for use for the line item to which they are obligated. SPECIAL ORDER REQUIREMENT PRODUCT FEATURES/SALIENT CHARACTERISTICS The following product features/characteristics are required for this requirement: Ten individual, unique hybridoma cell lines must be produced from animals previously inoculated for NCI with antibodies purified and sequenced against phospho-mEAK-7-Ser440. Each cell line shall include the following features: Antibody sequencing Antibody purification ELISA testing and validation that there is a strong positive signal to the phosphorylated peptide compared to the non-phosphorylated peptide. Antibodies must be produced via rabbit. Products must be delivered on dry ice. PERIOD OF PERFORMANCE The period of performance shall be for twelve (12) months from September 1, 2021 to August 31, 2022. PLACE OF PERFORMANCE The production shall be performed at the vendor’s location 860 Centennial Ave. Piscataway, NJ 08854 RESPONSE INSTRUCTIONS This notice is not a request for competitive quotations. However, if any interested party, especially a small business, believes it can meet the above requirement, it may submit a proposal or quote for the Government to consider. The response and any other information furnished must be in writing and must contain material in enough detail to allow NCI to determine if the party can perform the requirement. All responses must be submitted via email to Jolomi Omatete, Contracting Officer at jolomi.omatete@nih.gov. Responses are due no later than 5:00 P.M. ET Mondy, July 13, 2021 (07/13/2021). A determination by the Government not to compete this proposed requirement based upon responses to this notice is solely within the discretion of the Government. Information received will be considered solely for determining whether to conduct a competitive procurement. To receive an award, Contractors must be registered and have valid certification in the System for Award Management (SAM) through SAM.gov, and have Representations and Certifications filled out. Reference 75N91021Q00136 on all correspondence.